An overall and dose-response meta-analysis for thyrotropin and thyroid cancer risk by histological type

Na Hu; Zhan-Ming Li; Jin-Feng Liu; Zhen-Zhen Zhang; Li-Shun Wang

doi:10.18632/oncotarget.10282

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

An overall and dose-response meta-analysis for thyrotropin and thyroid cancer risk by histological type

Na Hu, Zhan-Ming Li, Jin-Feng Liu, Zhen-Zhen Zhang and Li-Shun Wang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:47750-47759. https://doi.org/10.18632/oncotarget.10282

Metrics: PDF 1671 views | HTML 2614 views | ?

Abstract

Na Hu1,2,*, Zhan-Ming Li3,*, Jin-Feng Liu1,2, Zhen-Zhen Zhang1,2, Li-Shun Wang1

1Institute of Biomedical Sciences, Minhang Hospital, Fudan University, Shanghai, P.R. China

2School of Public Health Taishan Medical University, Shandong, P.R. China

3Ruijin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, P.R. China

*These authors contributed equally to this work

Correspondence to:

Li-Shun Wang, email: [email protected]

Keywords: thyroid cancer, serum thyrotropin, meta-analysis, differentiated thyroid carcinoma, papillary thyroid carcinoma

Received: December 16, 2015 Accepted: June 12, 2016 Published: June 24, 2016

ABSTRACT

Thyrotropin (TSH) is thought as a risk factor for thyroid cancer. However, the effect of serum TSH might depend on histological types of thyroid cancer. We searched for related studies including serum TSH as an exposure and thyroid cancer as a result in PUBMED, EMBASE and Chinese National Knowledge Infrastructure up to April 21, 2016. This meta-analysis included 22 articles with 53,538 participants. When comparing all histological thyroid cancer, the pooled odds ratios of thyroid cancer in patients with nodules was found to increase significantly with higher serum TSH concentrations for differentiated thyroid carcinoma (1.88 vs .1.48, P = 0.0000) and papillary thyroid carcinoma (2.08 vs. 1.48, P = 0.0006). Each 1 mU/L increase of serum TSH was associated with 14% greater risk of thyroid cancer for all histological thyroid cancer, 16% for differentiated thyroid carcinoma and 22% for papillary thyroid carcinoma. In addition, high serum TSH was associated with a reduced risk for follicular thyroid carcinoma (OR = 0.73, 95% CI: 0.52, 1.02). This meta-analysis suggested high serum TSH concentration is risky for papillary thyroid carcinoma but not for follicular thyroid carcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10282

Publication Alerts

Research Papers:

An overall and dose-response meta-analysis for thyrotropin and thyroid cancer risk by histological type

Abstract